
Amgen’s denosumab may help check breast cancer in women with BRCA1 gene – Study
pharmafile | June 21, 2016 | News story | Manufacturing and Production, Research and Development | Amgen, Prolia, Xgeva, biotech, breast cancer, drug trial, genetics
US biotech firm Amgen’s (Nasdaq: AMGN) Prolia (denosumab) to treat osteoporosis and Xgeva to prevent fractures in cancer patients, may be an effective non-surgical alternative to prevent breast cancer associated with mutations in the BRCA1 gene, according to a pre-clinical study.
The study, published in in Nature Medicine, found that pre-cancerous BRCA1-mutated tissue could be identified by the RANK marker, the same protein targeted by denosumab.
The researchers evaluated breast tissue samples donated by women with BRCA1 mutations, finding that RANK+ cells proliferated rapidly, had faulty DNA repair and bore a molecular signature similar to that of basal-like breast cancer.
The study also found that proliferation was markedly reduced in breast biopsies from BRCA1-mutation carriers who were treated with denosumab, while inhibition of RANKL in a BRCA1-deficient mouse model substantially curtailed the formation of mammary tumours.
The protein produced by the BRCA1 gene normally plays a key role in repairing day-to-day DNA damage. BRCA1 is also regarded a tumor-suppressor gene due to its ability to regulate the repair of damaged DNA. However, when mutated, BRCA1 can allow cancer to occur with increased frequency.
Anjali Shukla
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Micrima announces upcoming launch of new UK breast cancer assessment
Breast cancer remains one of the leading health threats to women over 35 in the …

Pierre Fabre partners with Know Your Lemons Foundation for breast cancer awareness
The campaign focuses on early detection and education Pierre Fabre Laboratories has announced a partnership …






